Shattuck Labs is a clinical-stage biotech focused on inflammatory and immune-mediated disease, with lead work on DR3, the receptor for the cytokine TL1A. Its principal candidate SL-325 is a DR3-blocking monoclonal antibody being advanced for inflammatory bowel disease and related conditions. The approach aims for strong pathway blockade versus therapies that target TL1A itself.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -12.5 | — |
| Q3 2025 | 1 | — | -10.1 | — |
| Q4 2025 | 0 | — | -12.6 | — |
| Q1 2026 | 0 | — | -14.8 | — |
| Q2 2026 | 0 | — | -15.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Silence Therapeutics plc (SLN), Pacific Biosciences of California, Inc. (PACB), LightPath Technologies, Inc. (LPTH), The Honest Company, Inc. (HNST), Elevra Lithium Limited (ELVR), Backblaze, Inc. (BLZE)